2.4 C
New York
Saturday 27 November 2021

Buy now


HomePoliticsIndiaCovaxin effective against mutated coronavirus, study shows

Covaxin effective against mutated coronavirus, study shows

Harsh Vardhan had explained that Covaxin is more likely to work against newer variants like the UK variant and the double mutation


In a recent development, a study conducted by Clinical Infectious Diseases in collaboration with National Institute of Virology and Indian Council of Medical Research (ICMR) has revealed that the ‘made in India’ Covid-19 vaccine, which is Bharat Biotech’s Covaxin, produces neutralising titres against all new key variants of Covid-19 including the double mutant strain B.1.617 and B.1.1.7.

The peer-review publication, Clinical Infectious Diseases, on 16 May revealed the findings of the new study. The publication wrote, “Vaccination with Covaxin produced neutralising titres against all key emerging variants tested, including B.1.617 and B.1.1.7, first identified in India and the UK, respectively.”

The study found no difference in neutralisation between the UK variant and the strain (D614G).

“A modest reduction in neutralisation by a factor of 1.95 was observed against the B.1.617 variant compared to variant (D614G),” the manuscript said.

“No difference in neutralisation between B.1.1.7 (first isolated in the UK) and strain (D614G) was observed,” the manuscript added.

Earlier, Union Health Minister Dr Harsh Vardhan had explained that Covaxin is more likely to work against newer variants like the UK variant and the double mutation (Indian variant, B.1.617).

India-based Covaxin is an inactivated vaccine, which is made up of killed coronaviruses. Bharat Biotech used a sample of the coronavirus, isolated by India’s National Institute of Virology, to develop this vaccine. When administered, Covaxin immune cells can still recognise the dead virus, prompting the immune system to make antibodies against the pandemic virus.

This works by teaching the immune system to make antibodies against the -CoV-2 coronavirus.

The leading maker Bharat Biotech is ready to share the formula of its anti-Covid-19 Covaxin with other manufacturers. Aayog member Dr VK Paul informed that ‘Bharat Biotech has welcomed this decision’ on 13 May.

Dr VK Paul reportedly said, “People say that Covaxin be given to other companies for manufacturing. I am happy to say that Covaxin manufacturing company (Bharat Biotech) has welcomed this when we discussed it with them. Under this vaccine, live virus is inactivated & this is done only in BSL3 labs.”

Sirf News needs to recruit journalists in large numbers to increase the volume of its reports and articles to at least 100 a day, which will make us mainstream, which is necessary to challenge the anti-India discourse by established media houses. Besides there are monthly liabilities like the subscription fees of news agencies, the cost of a dedicated server, office maintenance, marketing expenses, etc. Donation is our only source of income. Please serve the cause of the nation by donating generously.

Support pro-India journalism by donating via UPI to surajit.dasgupta@icici

"Let's get more data to see how much of it is contributed by the #DeltaVariant and #Omicron," says Dr Randeep Guleria, Director, AIIMS, on the spike in #Covid cases in #SouthAfrica.

#Omicron #CovidVariant

Launched the website of Centre for Innovation and Incubation at Utkal University today. The CII will handhold young entrepreneurs and start-ups and act as a catalyst in creating a vibrant entrepreneurship ecosystem in Odisha.

BJP President Shri JP Nadda ji addressed the first workshop on ‘Samajik Samvad’, a new initiative of the party conceptualised by Sangathan Mantri Shri Santhosh ji to reach the newer sections of the society. @samajiksamvad @blsanthosh


‘মা কই?’, ফুল-ফুল জামা পরে ফুলের মতন মেয়েটা শুধু আঙুল উঁচিয়ে দেখাচ্ছিল চলন্ত ট্রেন…রহস্য সেখানেই

#DiamondHarbour | #LostChild


Read further:

This site uses Akismet to reduce spam. Learn how your comment data is processed.

- Advertisment -